SPARC submits cancer treatment drug for approval to USFDA

VADODARA (BARODA) | MUMBAI | AHMEDABAD – GANDHINAGAR | RAJKOT – In a press release issued to the Indian Stock Exchanges, Vadodara headquartered Sun Pharma Advanced Research Company (SPARC) Ltd said of having filed abbreviated new drug application (ANDA) for caner treatment to USFDA (US Food & Drugs Administration), which has been accepted by the regulator and is under standard review.

In a press release submitted to the Indian Bourses, the Indian pharma major’s research arm said that, SPARC Announces U.S. FDA Acceptance of NDA for Taclantis™ (Paclitaxel Injection Concentrate for Suspension) for Filing and Regulatory Review

Sun Pharma Advanced Research Company Ltd. (SPARC) (Reuters: SPRC.BO, Bloomberg: SPADV IN, NSE: SPARC, BSE: 532872) today announced that the U.S. Food and Drug Administration (USFDA) has accepted for review SPARC’s New Drug Application (NDA) for Taclantis™ (Paclitaxel Injection Concentrate for Suspension).

The NDA filing is based on successful demonstration of clinical bioequivalence of Taclantis™ with Abraxane® and associated clinical safety data.

SPARC seeks the same indications as Abraxane® for Taclantis™ in the NDA.

The USFDA confirmed that this NDA will be a standard review.


Taclantis™ (Paclitaxel Injection Concentrate for Suspension) is a Cremophor® and Albumin-free formulation of Paclitaxel.

It should be diluted with an appropriate volume of 5% w/v Dextrose injection in either a PVC or non-PVC type sterile infusion bag.

Premedication to prevent hypersensitivity is generally not needed prior to administration of Taclantis™.

Sun Pharma Advanced Research Company Ltd. (SPARC) is a global pharmaceutical company focused on continuously improving standards of care for patients globally through innovation in therapeutics and delivery.

SPARC aims to consistently lower costs and improve operational efficiencies to advance availability and affordability of cures for patients across the world.

More information about the company can be found at

For more information, please click the link, given here :




Do NOT follow this link or you will be banned from the site!